111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
单细胞和转录组测序的综合分析及实验验证揭示 SGO2 为乳腺癌的新型生物标志物
Authors Li YF, Yuan Y, Chen C, Zhu ML, Xu SY, Wu SQ, Gao Y, Meng LW
Received 18 August 2025
Accepted for publication 11 November 2025
Published 24 November 2025 Volume 2025:17 Pages 1083—1100
DOI https://doi.org/10.2147/BCTT.S561588
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Pranela Rameshwar
Yu-Fan Li,1,2 Ying Yuan,1,2 Cheng Chen,2,3 Ming-Liao Zhu,1,2 Shuo-Yang Xu,2,4 Shou-Qian Wu,1 Yuan Gao,2 Li-Wei Meng2
1Medical School of Shaoxing University, Shaoxing, Zhejiang, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Shaoxing People’s Hospital, The First Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, People’s Republic of China; 3State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 4The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Li-Wei Meng, Email menglw@usx.edu.cn
Purpose: SGO2 maintains the binding of sisters chromatids by protecting the adhesive complex at the centromere, thus ensuring the correct separation of chromosomes during mitosis and meiosis. And this study explored its role in breast cancer (BC) progression.
Methods: SGO2 expression in breast cancer was analyzed utilizing data from TCGA, GTEX, and HPA databases. Our study leveraged clinical data to predict outcomes. Subsequently, we conducted a GSEA enrichment analysis, dove into co-expression profiling, explored immune cell infiltration patterns, examined drug sensitivity, and analyzed single-cell data. To delve deeper, we validated the functional role of SGO2 through in vitro cellular experiments.
Results: Survival analysis demonstrated a notable correlation between heightened SGO2 expression and unfavorable cancer survival rates. Gene set enrichment analysis (GSEA) highlighted the participation of SGO2 in DNA replication. Immunoinfiltration analysis indicated a connection between SGO2 and several immune cell types, with single-cell analysis verifying SGO2 expression across diverse cell populations.
Conclusion: SGO2 may serve as a valuable prognostic biomarker and a potential therapeutic target in breast cancer.
Keywords: SGO2, BRCA, prognosis, immunity
1Medical School of Shaoxing University, Shaoxing, Zhejiang, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Shaoxing People’s Hospital, The First Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, People’s Republic of China; 3State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 4The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Li-Wei Meng, Email menglw@usx.edu.cn
Purpose: SGO2 maintains the binding of sisters chromatids by protecting the adhesive complex at the centromere, thus ensuring the correct separation of chromosomes during mitosis and meiosis. And this study explored its role in breast cancer (BC) progression.
Methods: SGO2 expression in breast cancer was analyzed utilizing data from TCGA, GTEX, and HPA databases. Our study leveraged clinical data to predict outcomes. Subsequently, we conducted a GSEA enrichment analysis, dove into co-expression profiling, explored immune cell infiltration patterns, examined drug sensitivity, and analyzed single-cell data. To delve deeper, we validated the functional role of SGO2 through in vitro cellular experiments.
Results: Survival analysis demonstrated a notable correlation between heightened SGO2 expression and unfavorable cancer survival rates. Gene set enrichment analysis (GSEA) highlighted the participation of SGO2 in DNA replication. Immunoinfiltration analysis indicated a connection between SGO2 and several immune cell types, with single-cell analysis verifying SGO2 expression across diverse cell populations.
Conclusion: SGO2 may serve as a valuable prognostic biomarker and a potential therapeutic target in breast cancer.
Keywords: SGO2, BRCA, prognosis, immunity